NASDAQ:ALIM Alimera Sciences (ALIM) Stock Price, News & Analysis $5.52 0.00 (0.00%) (As of 07/2/2024 ET) Add Compare Share Share Today's Range$5.52▼$5.5350-Day Range$2.89▼$5.5652-Week Range$2.60▼$5.65Volume189,082 shsAverage Volume193,574 shsMarket Capitalization$289.19 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Alimera Sciences alerts: Email Address Alimera Sciences MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside44.9% Upside$8.00 Price TargetShort InterestHealthy0.18% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 11 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.13) to $0.21 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.13 out of 5 starsMedical Sector339th out of 914 stocksPharmaceutical Preparations Industry158th out of 433 stocks 3.0 Analyst's Opinion Consensus RatingAlimera Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageAlimera Sciences has only been the subject of 3 research reports in the past 90 days.Read more about Alimera Sciences' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.18% of the outstanding shares of Alimera Sciences have been sold short.Short Interest Ratio / Days to CoverAlimera Sciences has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alimera Sciences has recently decreased by 25.43%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlimera Sciences does not currently pay a dividend.Dividend GrowthAlimera Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALIM. Previous Next 3.0 News and Social Media Coverage News SentimentAlimera Sciences has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Alimera Sciences this week, compared to 2 articles on an average week.Search Interest4 people have searched for ALIM on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Alimera Sciences to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alimera Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders31.40% of the stock of Alimera Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.83% of the stock of Alimera Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alimera Sciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Alimera Sciences are expected to grow in the coming year, from ($0.13) to $0.21 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alimera Sciences is -3.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alimera Sciences is -3.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlimera Sciences has a P/B Ratio of 6.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Alimera Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad StockEarningsRe: We’re giving you all this for less than a pair of socksThe Only Trading Tool You'll Need This Year Forget juggling multiple subscriptions and confusing indicators... Our all-in-one Premium Membership gives you everything you need to potentially profit in any market. Members have seen gains of 76.2%, 85.6%, and even 111.3% on single trades. This July 4th, get 12 months of access for just $4. Don't let this unprecedented offer slip away. About Alimera Sciences Stock (NASDAQ:ALIM)Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.Read More ALIM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALIM Stock News HeadlinesJuly 2 at 6:35 PM | prnewswire.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. - ALIMJune 29 at 4:46 AM | americanbankingnews.comAlimera Sciences, Inc. (NASDAQ:ALIM) Sees Large Decline in Short InterestJuly 2, 2024 | Behind the Markets (Ad)AI depends on this... Your retirement could too!Imagine owning a piece of the backbone powering the AI revolution. Wall Street says it's extremely undervalued - a downright steal compared to peers. We call it the "Last Retirement Stock You'll Ever Need."June 27, 2024 | americanbankingnews.comAlimera Sciences (NASDAQ:ALIM) Rating Reiterated by Alliance Global PartnersJune 26, 2024 | americanbankingnews.comAnalysts Issue Forecasts for Alimera Sciences, Inc.'s Q1 2025 Earnings (NASDAQ:ALIM)June 26, 2024 | americanbankingnews.comAlimera Sciences (NASDAQ:ALIM) Lowered to "Neutral" at HC WainwrightJune 26, 2024 | americanbankingnews.comAlimera Sciences (NASDAQ:ALIM) Given Hold Rating at Maxim GroupJune 25, 2024 | americanbankingnews.comAlimera Sciences (NASDAQ:ALIM) Stock Passes Above Two Hundred Day Moving Average of $3.64July 2, 2024 | Behind the Markets (Ad)AI depends on this... Your retirement could too!Imagine owning a piece of the backbone powering the AI revolution. Wall Street says it's extremely undervalued - a downright steal compared to peers. We call it the "Last Retirement Stock You'll Ever Need."June 24, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Alimera Sciences, Inc. has obtained a Fair Price for its Public ShareholdersJune 24, 2024 | investorplace.comWhy Is Alimera Sciences (ALIM) Stock Up 77% Today?June 24, 2024 | globenewswire.comALIM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Alimera Sciences to ANI PharmaceuticalsJune 24, 2024 | businesswire.comALIM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alimera Sciences, Inc. Is Fair to ShareholdersJune 4, 2024 | globenewswire.comAlimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 16, 2024 | markets.businessinsider.comRobust Growth and Promising Trials: Buy Rating for Alimera SciencesMay 15, 2024 | finance.yahoo.comAlimera Sciences Inc (ALIM) Q1 2024 Earnings Call Transcript Highlights: Soaring Revenues and ...May 14, 2024 | globenewswire.comAlimera Sciences Reports First Quarter 2024 ResultsMay 7, 2024 | finance.yahoo.comAlimera Announces Scientific Data Highlighting YUTIQ® to be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress ConferencesApril 30, 2024 | finance.yahoo.comAlimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate UpdateApril 3, 2024 | finance.yahoo.comLuckie & Company Acquires Marbury Creative GroupApril 3, 2024 | bizjournals.comLuckie & Co. acquires Atlanta marketing agencyMarch 26, 2024 | finance.yahoo.comOcular Inflammation Treatment Market InsightAce Exclusive Report 2024-2031March 20, 2024 | finance.yahoo.comAlimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 19, 2024 | finanznachrichten.deAlimera Sciences, Inc.: Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina NetworkMarch 19, 2024 | finance.yahoo.comAlimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina NetworkMarch 19, 2024 | globenewswire.comAlimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina NetworkMarch 18, 2024 | msn.comMizuho downgrades Amylyx to Neutral after ALS trial setbackSee More Headlines Receive ALIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alimera Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/02/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALIM CUSIPN/A CIK1267602 Webwww.alimerasciences.com Phone(678) 990-5740Fax678-990-5744Employees154Year Founded2003Price Target and Rating Average Stock Price Target$8.00 High Stock Price Target$10.00 Low Stock Price Target$6.00 Potential Upside/Downside+44.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,130,000.00 Net Margins-23.74% Pretax Margin-23.68% Return on Equity-53.49% Return on Assets-9.32% Debt Debt-to-Equity Ratio1.71 Current Ratio2.62 Quick Ratio2.51 Sales & Book Value Annual Sales$90.22 million Price / Sales3.21 Cash FlowN/A Price / Cash FlowN/A Book Value$0.88 per share Price / Book6.27Miscellaneous Outstanding Shares52,389,000Free Float35,939,000Market Cap$289.19 million OptionableOptionable Beta1.27 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Richard S. Eiswirth Jr. (Age 56)CEO & Director Comp: $949.27kMr. Jason Werner (Age 46)Chief Operating Officer Comp: $225.66kDr. Philip Ashman Ph.D. (Age 59)President of International Operations Comp: $516.98kMr. David R. Holland (Age 60)Co-Founder, Chief Marketing Officer and Senior VP of Corporate Communications & Managed Markets Comp: $413.5kMr. Elliot Maltz CPA (Age 39)CFO & Treasurer Christopher S. VisickVP, General Counsel & SecretaryDr. David Dyer M.D.Chief Retina SpecialistMr. Todd Michael Wood (Age 55)President of U.S. Operations More ExecutivesKey CompetitorsProthenaNASDAQ:PRTAArcutis BiotherapeuticsNASDAQ:ARQTDisc MedicineNASDAQ:IRONCollegium PharmaceuticalNASDAQ:COLLNurix TherapeuticsNASDAQ:NRIXView All CompetitorsInsiders & InstitutionsAncora Advisors LLCBought 234,620 shares on 5/16/2024Ownership: 0.448%Hillsdale Investment Management Inc.Bought 43,400 shares on 5/11/2024Ownership: 0.083%Vanguard Group Inc.Bought 396,506 shares on 5/10/2024Ownership: 1.996%Fifth Lane Capital LPBought 21,238 shares on 5/2/2024Ownership: 0.041%Caligan Partners LpBought 579,000 shares on 9/14/2023Total: $1.96 M ($3.39/share)View All Insider TransactionsView All Institutional Transactions ALIM Stock Analysis - Frequently Asked Questions Should I buy or sell Alimera Sciences stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ALIM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALIM, but not buy additional shares or sell existing shares. View ALIM analyst ratings or view top-rated stocks. What is Alimera Sciences' stock price target for 2024? 3 Wall Street analysts have issued twelve-month price targets for Alimera Sciences' stock. Their ALIM share price targets range from $6.00 to $10.00. On average, they anticipate the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 44.9% from the stock's current price. View analysts price targets for ALIM or view top-rated stocks among Wall Street analysts. How have ALIM shares performed in 2024? Alimera Sciences' stock was trading at $4.32 at the beginning of the year. Since then, ALIM stock has increased by 27.8% and is now trading at $5.52. View the best growth stocks for 2024 here. Are investors shorting Alimera Sciences? Alimera Sciences saw a drop in short interest in the month of June. As of June 15th, there was short interest totaling 94,700 shares, a drop of 25.4% from the May 31st total of 127,000 shares. Based on an average daily volume of 248,800 shares, the days-to-cover ratio is currently 0.4 days. View Alimera Sciences' Short Interest. When is Alimera Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our ALIM earnings forecast. How were Alimera Sciences' earnings last quarter? Alimera Sciences, Inc. (NASDAQ:ALIM) announced its earnings results on Tuesday, May, 14th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by $0.08. The biopharmaceutical company had revenue of $23.01 million for the quarter, compared to the consensus estimate of $23.72 million. Alimera Sciences had a negative trailing twelve-month return on equity of 53.49% and a negative net margin of 23.74%. During the same quarter last year, the company earned ($0.71) earnings per share. When did Alimera Sciences' stock split? Shares of Alimera Sciences reverse split before market open on Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 14th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What guidance has Alimera Sciences issued on next quarter's earnings? Alimera Sciences updated its FY 2024 earnings guidance on Tuesday, May, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $105.0 million-, compared to the consensus revenue estimate of $103.8 million. What is Rick Eiswirth's approval rating as Alimera Sciences' CEO? 2 employees have rated Alimera Sciences Chief Executive Officer Rick Eiswirth on Glassdoor.com. Rick Eiswirth has an approval rating of 100% among the company's employees. This puts Rick Eiswirth in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Alimera Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN), AngloGold Ashanti (AU), SSR Mining (SSRM), ADMA Biologics (ADMA) and Cellectar Biosciences (CLRB). How do I buy shares of Alimera Sciences? Shares of ALIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALIM) was last updated on 7/2/2024 by MarketBeat.com Staff From Our PartnersRe: We’re giving you all this for less than a pair of socksThe Only Trading Tool You'll Need This Year Forget juggling multiple subscriptions and confusing indicator...StockEarnings | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredWill Biden Be Replaced?There are growing rumors of a possible Joe Biden replacement following his first debate against Donald Trump. ...Stansberry Research | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine...InvestorPlace | Sponsored270x more lucrative than NVIDIA???If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that cou...Behind the Markets | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alimera Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alimera Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
